JAK1 and neoplasm: Nevertheless, both CD4 and CD8 ACT therapies substantially increased the number of myeloid cells in HCmel12 CRISPR-ctrl and HCmel12 Jak1-KO tumours (Fig. 1p and Extended Data Fig. 3d,e).